Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus chemotherapy versus osimertinib alone in first-line EGFR-mutant NSCLC with concomitant mutations
ChiCTR2100045604Phase 3Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: Progression-free survival, Overall survival and 3 more. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100045604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045604.